Zosano Pharma Corporation reported impairment charges for the first quarter ended March 31, 2022. For the quarter, the company reported impairment loss of $25.9 million for the three months ended March 31, 2022, consists of the write-down of $24.8 million of property and equipment and $1.1 million of right-of-use assets.
Zosano Pharma Corporation
Equities
ZSAN
US98979H3012
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-2.47% | 103B | |
+1.90% | 95.28B | |
+1.46% | 22.15B | |
-15.29% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.20% | 16.05B | |
+4.11% | 13.68B | |
+35.69% | 12.17B |